Medical Developments International Limited (MVP) Price & Analysis

Q: What was Medical Developments International Limited’s price range in the past 12 months?

Medical Developments International Limited lowest share price was AU$0.40 and its highest was AU$0.94 in the past 12 months.

Q: What is Medical Developments International Limited’s market cap?

Medical Developments International Limited’s market cap is AU$79.99M.

Q: When is Medical Developments International Limited’s upcoming earnings report date?

Medical Developments International Limited’s upcoming earnings report date is Aug 21, 2025 which is in 4 days.

Q: How were Medical Developments International Limited’s earnings last quarter?

Medical Developments International Limited released its earnings results on Feb 19, 2025. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of -AU$0.018 by AU$0.021.

Q: Is Medical Developments International Limited overvalued?

According to Wall Street analysts Medical Developments International Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Medical Developments International Limited pay dividends?

Medical Developments International Limited pays a Semiannually dividend of AU$0.019 which represents an annual dividend yield of N/A. See more information on Medical Developments International Limited dividends here

Q: What is Medical Developments International Limited’s EPS estimate?

Medical Developments International Limited’s EPS estimate is -0.01.

Q: How many shares outstanding does Medical Developments International Limited have?

Medical Developments International Limited has 112,658,325 shares outstanding.

Q: What happened to Medical Developments International Limited’s price movement after its last earnings report?

Medical Developments International Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of -AU$0.018. Following the earnings report the stock price went up 10.526%.

Q: Which hedge fund is a major shareholder of Medical Developments International Limited?

Currently, no hedge funds are holding shares in AU:MVP

Compare

8 Followers

MVP Stock Chart & Stats

Day’s Range― - ―

52-Week RangeAU$0.40 - AU$0.94

Previous CloseN/A

Volume7.44K

Average Volume (3M)153.82K

Market Cap

AU$79.99M

Enterprise ValueAU$30.12M

Total Cash (Recent Filing)AU$17.62M

Total Debt (Recent Filing)AU$2.14M

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Aug 21, 2025

EPS Estimate

-0.01

Last Dividend Ex-Date

Mar 05, 2020

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding112,658,325

10 Day Avg. Volume170,559

30 Day Avg. Volume153,819

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.66

Price Target Upside-7.04% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Medical Developments International Limited News

Medical Developments International Ltd to Announce FY25 Financial Results

An announcement from Medical Developments International Limited ( ($AU:MVP) ) is now available. Medical Developments International Ltd is...

4d ago

MVP

Medical Developments International Achieves Positive Cash Flow and Expands Penthrox Market

Medical Developments International Limited ( ($AU:MVP) ) just unveiled an update. Medical Developments International Limited reported a positive...

17d ago

MVP

Medical Developments International Issues New Performance Rights

An update from Medical Developments International Limited ( ($AU:MVP) ) is now available. Medical Developments International Limited announced...

3M ago

MVP

Medical Developments International Appoints New Director to Drive Strategic Growth

Medical Developments International Limited ( ($AU:MVP) ) has issued an update. Medical Developments International Limited announced the resignation...

3M ago

MVP

Medical Developments International Reports Strong Q3 FY25 Performance

Medical Developments International Limited ( ($AU:MVP) ) has shared an update. Medical Developments International Limited reported strong financial...

4M ago

MVP

Medical Developments International Appoints New Director

Medical Developments International Limited ( ($AU:MVP) ) has shared an announcement. Medical Developments International Limited has announced the...

5M ago

MVP

Medical Developments International Achieves Financial Turnaround with Strong Half-Year Results

The latest update is out from Medical Developments International Limited ( ($AU:MVP) ). Medical Developments International reported a...

6M ago

MVP

Medical Developments International Limited FY25 Half-Year Results Overview

Medical Developments International Limited ( ($AU:MVP) ) has provided an update. Medical Developments International Limited has released its...

6M ago

MVP

Medical Developments International Reports Strong Half-Year Growth

The latest update is out from Medical Developments International Limited ( ($AU:MVP) ). Medical Developments International Limited reported...

6M ago

MVP

Medical Developments International to Announce FY25 Half-Year Results

Medical Developments International Limited ( ($AU:MVP) ) has shared an update. Medical Developments International Ltd announced that it...

6M ago

MVP

MVP FAQ

What was Medical Developments International Limited’s price range in the past 12 months?

Medical Developments International Limited lowest share price was AU$0.40 and its highest was AU$0.94 in the past 12 months.

What is Medical Developments International Limited’s market cap?

Medical Developments International Limited’s market cap is AU$79.99M.

When is Medical Developments International Limited’s upcoming earnings report date?

Medical Developments International Limited’s upcoming earnings report date is Aug 21, 2025 which is in 4 days.

How were Medical Developments International Limited’s earnings last quarter?

Medical Developments International Limited released its earnings results on Feb 19, 2025. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of -AU$0.018 by AU$0.021.

Is Medical Developments International Limited overvalued?

According to Wall Street analysts Medical Developments International Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medical Developments International Limited pay dividends?

Medical Developments International Limited pays a Semiannually dividend of AU$0.019 which represents an annual dividend yield of N/A. See more information on Medical Developments International Limited dividends here

What is Medical Developments International Limited’s EPS estimate?

Medical Developments International Limited’s EPS estimate is -0.01.

How many shares outstanding does Medical Developments International Limited have?

Medical Developments International Limited has 112,658,325 shares outstanding.

What happened to Medical Developments International Limited’s price movement after its last earnings report?

Medical Developments International Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of -AU$0.018. Following the earnings report the stock price went up 10.526%.

Which hedge fund is a major shareholder of Medical Developments International Limited?

Currently, no hedge funds are holding shares in AU:MVP

Medical Developments International Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

-45.40%

Trailing 12-Months

Asset Growth

-28.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medical Developments International Limited

Medical Developments International Limited (MVP) is a global company specializing in the development, manufacture, and distribution of innovative medical technologies. MVP operates primarily in the healthcare sector, focusing on products that enhance patient care in areas such as pain management, respiratory support, and veterinary applications. The company's flagship offering is the Penthrox inhaler, a fast-acting pain relief solution widely used in emergency settings and minor surgical procedures. Additionally, MVP provides a range of respiratory devices and veterinary equipment, catering to both human and animal health needs.

Medical Developments International Limited (MVP) Earnings & Revenues

Historic Earnings Reports

MVP Stock 12 Month Forecast

Average Price Target

AU$0.66

▼(-7.04% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"AU$6","-1":"-AU$1","0.75":"AU$0.75","2.5":"AU$2.5","4.25":"AU$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2022","6":"Feb<br/>2023","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.56,0.5792307692307693,0.5984615384615385,0.6176923076923078,0.6369230769230769,0.6561538461538462,0.6753846153846155,0.6946153846153846,0.7138461538461539,0.7330769230769232,0.7523076923076923,0.7715384615384616,0.7907692307692309,{"y":0.81,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.56,0.5676923076923077,0.5753846153846154,0.5830769230769232,0.5907692307692308,0.5984615384615385,0.6061538461538462,0.6138461538461539,0.6215384615384616,0.6292307692307693,0.6369230769230769,0.6446153846153847,0.6523076923076924,{"y":0.66,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.56,0.5553846153846155,0.5507692307692308,0.5461538461538462,0.5415384615384615,0.536923076923077,0.5323076923076924,0.5276923076923077,0.5230769230769231,0.5184615384615385,0.5138461538461538,0.5092307692307693,0.5046153846153846,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.74,"date":1601510400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1604188800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1627776000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1646092800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1664582400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1675209600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.52,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >